Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75(2):285–92.

Article  CAS  PubMed  Google Scholar 

Wu J, Du X, Lv Q, Li Z, Zheng Z, Xia Y, et al. A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension. Medicine (Baltimore). 2020;99(32): e21465.

Article  CAS  PubMed  Google Scholar 

Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012;380(9859):2224–60.

Article  Google Scholar 

Organization WH. Hypertension_WHO. 2023.

Bromfield S, Muntner P. High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs. Curr Hypertens Rep. 2013;15(3):134–6.

Article  PubMed  PubMed Central  Google Scholar 

Wang J, Ning X, Yang L, Lu H, Tu J, Jin W, et al. Trends of hypertension prevalence, awareness, treatment and control in rural areas of northern China during 1991–2011. J Hum Hypertens. 2014;28(1):25–31.

Article  PubMed  Google Scholar 

Wang J, Zhang L, Wang F, Liu L, Wang H. Prevalence, awareness, treatment, and control of hypertension in china: results from a national survey. Am J Hypertens. 2014;27(11):1355–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang JG, Zhang W, Li Y, Liu L. Hypertension in China: epidemiology and treatment initiatives. Nat Rev Cardiol. 2023;20(8):531–45.

Article  PubMed  Google Scholar 

Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, et al. Status of hypertension in China. Circulation. 2018;137(22):2344–56.

Article  PubMed  Google Scholar 

Feng XL, Pang M, Beard J. Health system strengthening and hypertension awareness, treatment and control: data from the China Health and Retirement Longitudinal Study. Bull World Health Organ. 2014;92(1):29–41.

Article  PubMed  Google Scholar 

Wang Z, Ma L, Liu M, F, Hu S. Summary of the 2022 report on cardiovascular health and diseases in China. 2023.

Lou Y, Ma W, Wang Z, Yang N, Sun Y, Liu Y, Lei R, Zhao J, Luo X, Wang L, Chen Y, Han Y, Sun Y, Li Y, Cai J. A protocol for developing Chinese clinical practice guidelines of hypertension. 2022. https://www.journalslwwcom/cd/pages/defaultaspx.

Zhi ZXXGBZ. Expert consensus on the comprehensive management of blood pressure and dyslipidemia in Chinese hypertensive patients. Zhonghua Xin Xue Guan Bing Za Zhi. 2021;49(6):554–63.

Google Scholar 

Campbell NRC, Zhang X-H. Hypertension in China. Circulation. 2018;137(22):2357–9.

Article  PubMed  Google Scholar 

Liu J. Highlights of the 2018 Chinese hypertension guidelines. Clin Hypertens. 2020. https://doi.org/10.1186/s40885-020-00141-3.

Article  PubMed  PubMed Central  Google Scholar 

Bangalore S, Fakheri R, Toklu B, Ogedegbe G, Weintraub H, Messerli FH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc. 2016;91(1):51–60.

Article  CAS  PubMed  Google Scholar 

Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2012;12(4):263–77.

Article  CAS  PubMed  Google Scholar 

Ross SD, Akhras KS, Zhang S, Rozinsky M, Nalysnyk L. Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis. Pharmacotherapy. 2001;21(8):940–53.

Article  CAS  PubMed  Google Scholar 

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ. Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023): Cochrane. 2023. www.training.cochrane.org/handbook.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021: n71.

Google Scholar 

Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(Oct 18 2):d5928.

Article  PubMed  PubMed Central  Google Scholar 

Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163–71.

Article  PubMed  Google Scholar 

Owen RK, Bradbury N, Xin Y, Cooper N, Sutton A. MetaInsight: an interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta. Res Synth Methods. 2019;10(4):569–81.

Article  PubMed  PubMed Central  Google Scholar 

Xin Y CN, Owen RK, Freeman S, Sutton AJ. MetaInsight user guide—(including Bayesian functionality) version 0.1. https://crsu.shinyapps.io/metainsight.

Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich). 2007;9(9):667–76.

Article  CAS  PubMed  Google Scholar 

Weber MA, Bakris GL, Tarka EA, Iyengar M, Fleck R, Sica DA. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006;8(12):840–9.

Article  CAS  PubMed  Google Scholar 

Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698–705.

Article  CAS  PubMed  Google Scholar 

White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57(3):413–20.

Article  CAS  PubMed  Google Scholar 

Greathouse M. Nebivolol efficacy and safety in patients with stage I-II hypertension. Clin Cardiol. 2010;33(4):E20–7.

Article  PubMed  PubMed Central  Google Scholar 

Ruzicka M, Coletta E, Floras J, Leenen FH. Effects of low-dose nifedipine GITS on sympathetic activity in young and older patients with hypertension. J Hypertens. 2004;22(5):1039–44.

Article  CAS  PubMed  Google Scholar 

Perez A, Cao C. The impact of azilsartan medoxomil treatment (capsule formulation) at doses ranging from 10 to 80 mg: significant, rapid reductions in clinic diastolic and systolic blood pressure. J Clin Hypertens (Greenwich). 2017;19(3):312–21.

Article  CAS  PubMed  Google Scholar 

Neutel JM, Germino FW, Smith D. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst. 2005;6(2):84–9.

Article  CAS  PubMed  Google Scholar 

Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich). 2007;9(11):866–75.

Article  CAS  PubMed  Google Scholar 

Zanchetti A, Omboni S. Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group. Am J Hypertens. 2001;14(2):129–34.

Article  CAS  PubMed  Google Scholar 

Leenen FH, Tanner J, McNally CF. Antihypertensive efficacy of the ACE-inhibitor perindopril in the elderly. J Hum Hypertens. 2000;14(5):321–5.

Article  CAS  PubMed  Google Scholar 

Dingemanse J, Otasevic P, Shakeri-Nejad K, Klainman E, Putnikovic B, Kracker H, et al. Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension. J Hum Hypertens. 2015;29(4):229–35.

Article  CAS  PubMed